Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

2017 J Mark Access Health Policy

Medic, G. | Korchagina, D. | Young, K. E. | Toumi, M. | Postma, M. J. | Wille, M. | Hemels, M. | Volume: 5, Issue: 1, Pages: 1299665, Europe, Rare diseases, orphan drugs, pricing, treatment cost,

Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and the annual treatment cost of orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK. Methods: Approved orphan drugs and prevalence data were extracted from the European Medicines Agency website. Annual treatment costs were calculated using ex-factory price. Simple regression was used to analyse the relationship between costs and prevalence. A specific bivariate analysis was performed for the rarest diseases (

https://www.doi.org/10.1080/20016689.2017.1299665